← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV25행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
biological agent (Seneca Valley Virus, Seneca Valley Virus (biological agent))
Neotropix·Carcinoid
93 trials
Overview
Program
Seneca Valley Virus (biological agent)
Overview
Company
Neotropix
Overview
Modality
CGT
Overview
Target
Carcinoid
Overview
Indication
Carcinoid; Neuroendocrine
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Vector
lentiviral entry, particularly in A549-ACE2 cells, although differences were not statistic
MoA
Mechanism
Inhibits Senecavirus A Replication by Activating IKBKE-Mediated IFN Pathway
MoA
Biomarker
biomarkers
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat, In vitro
Toxicology
Major finding
The porcine-derived compound Bacillus alleviates piglet infection with porcine epidemic diarrhea virus by reshaping the intestinal barrier and microbial balance.. Porcine epidemic diarrhea virus (PEDV) causes severe intestinal injury and high mortality in suckling piglets, resulting in massive economic losses worldwide. Due to the continuous emergence of variant strains, traditional vaccines canno…
Clinical
Safety signal
The porcine-derived compound Bacillus alleviates piglet infection with porcine epidemic diarrhea virus by reshaping the intestinal barrier and microbial balance.. Porcine epidemic diarrhea virus (PEDV) causes severe intestinal injury and high mortality in suckling piglets, resulting in massive economic losses worldwide. Due to the continuous emergence of variant strains, traditional vaccines canno…
Clinical
Result source
ClinicalTrials.gov NCT00006237
Clinical
Program phase
PHASE_1
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT00006237